Format

Send to

Choose Destination
J Am Heart Assoc. 2019 Nov 19;8(22):e012881. doi: 10.1161/JAHA.119.012881. Epub 2019 Nov 12.

Serial Plasma Phospholipid Fatty Acids in the De Novo Lipogenesis Pathway and Total Mortality, Cause-Specific Mortality, and Cardiovascular Diseases in the Cardiovascular Health Study.

Author information

1
Friedman School of Nutrition Science and Policy Tufts University Boston MA.
2
Department of Epidemiology Human Genetics and Environmental Sciences University of Texas Health Science Center at Houston TX.
3
The George Institute for Global Health Faculty of Medicine University of New South Wales Newtown NSW Australia.
4
Fred Hutchinson Cancer Research Center Seattle WA.
5
Department of Internal Medicine University of New Mexico Albuquerque NM.
6
Department of Medicine, Epidemiology, and Health Services University of Washington Seattle WA.
7
Cardiovascular Health Research Unit Department of Medicine University of Washington Seattle WA.
8
Kaiser Permanente Washington Health Research Institute Seattle WA.
9
Department of Biostatistics University of Washington Seattle WA.
10
The New York Academy of Medicine New York City NY.

Abstract

Background Synthesized fatty acids (FAs) from de novo lipogenesis may affect cardiometabolic health, but longitudinal associations between serially measured de novo lipogenesis-related fatty acid biomarkers and mortality or cardiovascular disease (CVD) are not well established. Methods and Results We investigated longitudinal associations between de novo lipogenesis-related fatty acids with all-cause mortality, cause-specific mortality, and incident CVD among 3869 older US adults, mean (SD) age 75 (5) years and free of prevalent CVD at baseline. Levels of plasma phospholipid palmitic (16:0), palmitoleic (16:1n-7), stearic (18:0), oleic acid (18:1n-9), and other risk factors were serially measured at baseline, 6 years, and 13 years. All-cause mortality, cause-specific mortality, and incident fatal and nonfatal CVD were centrally adjudicated. Risk was assessed in multivariable-adjusted Cox models with time-varying FAs and covariates. During 13 years, median follow-up (maximum 22.4 years), participants experienced 3227 deaths (1131 CVD, 2096 non-CVD) and 1753 incident CVD events. After multivariable adjustment, higher cumulative levels of 16:0, 16:1n-7, and 18:1n-9 were associated with higher all-cause mortality, with extreme-quintile hazard ratios (95% CIs) of 1.35 (1.17-1.56), 1.40 (1.21-1.62), and 1.56 (1.35-1.80), respectively, whereas higher levels of 18:0 were associated with lower mortality (hazard ratio=0.76; 95% CI=0.66-0.88). Associations were generally similar for CVD mortality versus non-CVD mortality, as well as total incident CVD. Changes in levels of 16:0 were positively, and 18:0 inversely, associated with all-cause mortality (hazard ratio=1.23, 95% CI=1.08-1.41; and hazard ratio=0.78, 95% CI=0.68-0.90). Conclusions Higher long-term levels of 16:0, 16:1n-7, and 18:1n-9 and changes in 16:0 were positively, whereas long-term levels and changes in 18:0 were inversely, associated with all-cause mortality in older adults.

KEYWORDS:

cardiovascular disease; de novo lipogenesis; fatty acid biomarkers; longitudinal analysis; mortality

PMID:
31711385
DOI:
10.1161/JAHA.119.012881
Free full text

Supplemental Content

Full text links

Icon for Atypon
Loading ...
Support Center